Stryker Introduces Mako Handheld Robotics with RPS Launch

Why It Matters

By offering a handheld, easier‑to‑adopt robotic solution, Stryker can accelerate adoption of robotics in knee arthroplasty and capture a segment of surgeons resistant to complex systems, potentially boosting procedure volumes and market share.

Key Takeaways

• Handheld Mako RPS launches limited market rollout
• Integrates robotic guidance with traditional power tools
• Compatible with Triathlon Total Knee System
• Simplifies workflow, no cutting blocks needed
• Aims to capture surgeons seeking easier robotics

Pulse Analysis

The orthopaedic robotics market has matured over the past two decades, with Stryker’s Mako platform becoming a benchmark for total knee and hip procedures. As hospitals seek to justify capital expenditures, the industry has seen a shift toward solutions that deliver comparable precision with lower acquisition costs and reduced training burdens. Stryker’s latest handheld offering, the Mako Robotic Power System (RPS), arrives at this inflection point, promising to extend the brand’s reach beyond the high‑volume, robot‑arm segment.

Unlike traditional robotic arms that require a separate console and pre‑drilled cutting blocks, the Mako RPS integrates a robotically enabled saw directly into the surgeon’s handpiece. The system’s active‑adjustment technology continuously monitors hand movements and automatically corrects the blade trajectory to stay within the pre‑operative plan. This intra‑operative planning capability, combined with compatibility with the Triathlon Total Knee System, allows surgeons to maintain a familiar tactile feel while benefiting from real‑time guidance, potentially shortening case times and improving alignment accuracy.

Strategically, the handheld platform positions Stryker to capture a broader surgeon base that has been hesitant to adopt full‑scale robots due to workflow disruption and cost. By simplifying the learning curve, the RPS could accelerate procedure volumes and reinforce Stryker’s leadership against competitors such as Zimmer Biomet’s Rosa and Medtronic’s Mazor. If the limited rollout proves successful at the upcoming AAOS meeting, the company may expand distribution quickly, turning the RPS into a catalyst for the next wave of robotics‑driven growth in joint replacement.